


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">31199098</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1526-744X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>46</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <MedlineDate>2019 May-Jun</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Nephrology nursing journal : journal of the American Nephrology Nurses' Association</Title>
                <ISOAbbreviation>Nephrol Nurs J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Administration of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with CKD-MBD on Hemodialysis: A Nephrology Nursing Perspective.</ArticleTitle>
            <Pagination>
                <MedlinePgn>315-290</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The number, volume, and timing of oral medications prescribed to treat secondary hyperparathyroidism can add to the burden of disease management for both the patient and the nurse. Administering intravenous (IV) medication when possible has the potential of reducing the burden of medication management. Data on the use of IV calcimimetic etelcalcetide has shown improvement in blood calcium, phosphorus, and parathyroid hormone levels. IV administration of etelcalcetide at the end of each hemodialysis session may reduce the pill burden for patients and has the potential to help improve disease management within an environment that supports person-centered care.</AbstractText>
                <CopyrightInformation>CopyrightÂ© by the American Nephrology Nurses Association.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hain</LastName>
                    <ForeName>Debra</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Professor, MSN Coordinator: AGNP Concentration, Florida Atlantic University, Christine E Lynn College of Nursing, Boca Raton, FL.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Nurse Practitioner, Cleveland Clinic Florida, Department of Nephrology, Weston, FL.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>President-Elect of ANNA's South Florida Flamingo Chapter.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomlin</LastName>
                    <ForeName>Holly</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Consultant, Tomlin Science Communications.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gibson</LastName>
                    <ForeName>Cristian</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Senior Regional Medical Liaison, Amgen Inc., Thousand Oaks, CA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nephrol Nurs J</MedlineTA>
            <NlmUniqueID>100909377</NlmUniqueID>
            <ISSNLinking>1526-744X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">calcimimetic</Keyword>
            <Keyword MajorTopicYN="N">etelcalcetide</Keyword>
            <Keyword MajorTopicYN="N">nephrology</Keyword>
            <Keyword MajorTopicYN="N">nursing</Keyword>
            <Keyword MajorTopicYN="N">secondary hyperparathyroidism</Keyword>
        </KeywordList>
        <CoiStatement>The author reported no actual or potential conflict of interest in relation to this continuing nursing education activity.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199098</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

